Top Story Today
The Nobel Prize Just Went to Scientists Who Learned to Control the Brain With Light
The 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, Peter Hegemann, and Georg Nagel for optogenetics: the ability to turn individual brain cells on and off with light. The origin story starts with a protein from pond algae that senses light, which Deisseroth's lab repurposed to control neurons in 2005. Two decades later, the technology is already in late-stage clinical trials for inherited blindness (Nanoscope Therapeutics leads with Phase 2b/3 data), and researchers are using it to map the circuits that break down in Alzheimer's and depression.
Why it matters: The Nobel committee called optogenetics 'only the beginning,' and they weren't being modest. This prize validates a technology that's reshaping both basic neuroscience and translational medicine, with the first regulatory approvals for blindness treatments potentially months away.
Read more →Deals and M&A
Novartis Just Bet $7.8 Billion That mRNA Can Do Way More Than Vaccines
Novartis signed a deal worth up to $7.8 billion with China's Abogen Biosciences for an mRNA drug that instructs your body to build its own autoimmune therapy. The $575 million upfront payment buys rights to ABO2203, an mRNA-encoded T-cell engager targeting B-cell depletion, plus options on Abogen's broader RNA platform.
Read more →AstraZeneca Drops $2 Billion on a Drug It Doesn't Even Own
AstraZeneca bought a 12% stake in Summit Therapeutics for $2 billion without licensing its star cancer drug, ivonescimab. The real play is a clinical collaboration pairing Summit's bispecific antibody (which blocks both PD-1 and VEGF simultaneously) with AstraZeneca's ADC portfolio. The bet: hitting tumors from three directions at once could define the next era of combination cancer therapy.
Read more →Shionogi Pays $2 Billion Cash for a Tiny Texas Rare Disease Biotech
Japanese pharma giant Shionogi agreed to buy IntraBio for $2 billion in cash. The prize: Aqneursa, the only FDA-approved treatment for both Niemann-Pick disease type C and ataxia-telangiectasia, plus IntraBio's pipeline in GM2 gangliosidoses and CACNA1A-related disorders. It's the latest in a wave of Japanese pharma companies snapping up U.S. rare disease assets.
Read more →CSL Bets $1.6 Billion on a Rogue Protein in Scarred Organs
CSL handed Swiss startup Alentis Therapeutics $355 million upfront (up to $1.6 billion total) to co-develop lixudebart, an antibody targeting claudin-1, a protein that goes rogue in fibrotic kidney and liver disease. The mechanism is first-in-class, but hard efficacy data is still pending. CSL is betting early on a platform that could span multiple rare organ diseases.
Read more →Clinical and Regulatory
The Drug That Could Rewrite Frontline Treatment for the Most Common Aggressive Lymphoma
AbbVie and Genmab's epcoritamab (Epkinly) cut the risk of disease progression or death by 51% when added to standard R-CHOP chemo in newly diagnosed DLBCL, the most common aggressive lymphoma. After roughly 30 years of the same standard of care, this is the first bispecific antibody to hit a Phase 3 endpoint in frontline DLBCL. Analysts have pegged peak sales at $2.75 billion.
Read more →The FDA Is Investigating Patient Deaths Linked to Sarepta's Duchenne Gene Therapy
Three fatal cases of acute liver failure in patients receiving Sarepta's AAV-based gene therapies prompted the FDA to suspend distribution and pause clinical trials. The deaths were concentrated in non-ambulatory Duchenne patients. Sarepta has since resumed shipments for ambulatory patients, but the investigation raises hard questions about the risk profile of high-dose systemic gene therapies across the field.
Read more →The FDA Just Cleared a Phone App to Treat Schizophrenia
No conventional drug has ever been FDA-approved for the negative symptoms of schizophrenia (the loss of motivation, emotion, and social drive that devastates long-term outcomes). Click Therapeutics' Motivista, a prescription smartphone app, just became the first authorized treatment for those symptoms, backed by a randomized, double-blind Phase 3 trial showing statistically significant improvement.
Read more →A Pill That Could Replace Daily Injections for Kids With Achondroplasia
The FDA granted Priority Review to BridgeBio's oral infigratinib for achondroplasia, with a decision date of February 4, 2027. If approved, it would be the first oral therapy for the most common form of dwarfism, replacing the daily injections that current treatments require. Phase 3 data showed kids grew about 2 cm/year faster than placebo.
Read more →Funding and Policy
Europe's Biggest Biotech Fund Just Got a Lot Bigger
Dutch VC firm Forbion closed two funds totaling 2.3 billion euros, the largest European life sciences fundraise in recent memory. Backers include KfW Capital, major Dutch pension funds, and Eli Lilly. It's a massive vote of confidence in European biotech, though the continent still captures just 7% of global life sciences VC. The funds plan to back roughly 30 companies.
Read more →The FDA Just Asked the Public to Help Design an Ibogaine Drug Trial
The FDA opened a public comment period seeking input on how to design early-phase clinical trials for ibogaine, a psychoactive compound that shows promise for opioid addiction but carries serious cardiac risks. It's an unusual crowdsourcing move that signals growing regulatory seriousness about psychedelic medicine. Comments are due November 20.
Read more →